Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)

Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval

AbbVie agrees to acquire Capstan Therapeutics

Sanofi's riliprubart receives orphan drug designation in Japan for CIDP

Galderma launches two phase II trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin

Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions

Harbour BioMed and Otsuka collaborate on advancing BCMAxCD3 bispecific T-cell engagers

Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis

Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease

RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis

Sanofi acquires DR-0201 from Dren Bio to expand immunology pipeline

Celltrion announces FDA interchangeability designation for all YUFLYMA's approved dosage forms and strengths

InnoCare reports first patient dosed in Phase II/III vitiligo trial

First participant dosed in second head-to-head Phase 3 study of mazdutide versus semaglutide in China

AB Science reports masitinib shows neuroprotective potential in preclinical model of neurodegeneration